AffaMed Therapeutics is a late clinical-stage biopharmaceutical company developing pharmaceutical products for ophthalmic conditions, including DEXTENZA® for ocular inflammation and pain management. The company addresses critical unmet medical needs in ophthalmology, particularly for patients suffering from conditions like intermediate dry age-related macular degeneration and post-surgical ocular inflammation.
Funding
$170M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many ophthalmic conditions, such as post-surgical inflammation, allergic conjunctivitis, and intermediate dry age-related macular degeneration (AMD), lack effective pharmaceutical treatments, leading to prolonged discomfort, potential vision loss, and reduced quality of life for patients. Current treatments may have limited efficacy or undesirable side effects, creating a need for innovative and targeted therapies.
Solution
AffaMed Therapeutics is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for ophthalmic conditions. Their pipeline includes DEXTENZA®, a product for managing ocular inflammation and pain, and Risuteganib (Luminate®), a candidate for treating intermediate dry AMD. By focusing on areas with high unmet medical needs, AffaMed aims to provide transformative treatments that improve patient outcomes and address the challenges associated with prevalent eye diseases. The company seeks to bridge the gap between global innovative solutions and patient needs in ophthalmology.
Target Audience
The primary target audience includes patients suffering from ophthalmic conditions such as post-surgical ocular inflammation, allergic conjunctivitis, and intermediate dry age-related macular degeneration, as well as ophthalmologists and healthcare providers seeking advanced treatment options.
Features
- DEXTENZA®: A product for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.
- Risuteganib (Luminate®): A first-in-class candidate for the treatment of intermediate dry AMD.
- Focus on developing and commercializing innovative therapies for major disease states in ophthalmology.
- Clinical-stage development programs targeting critical unmet medical needs.
- Licensing of EVOLUX®: A novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL.